Genmab A/S ADR (GMAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
GMAB POWR Grades
- GMAB scores best on the Value dimension, with a Value rank ahead of 78.62% of US stocks.
- GMAB's strongest trending metric is Value; it's been moving up over the last 177 days.
- GMAB's current lowest rank is in the Momentum metric (where it is better than 4.75% of US stocks).
GMAB Stock Summary
- With a market capitalization of $24,643,243,673, GENMAB A has a greater market value than 91.38% of US stocks.
- With a price/sales ratio of 11.85, GENMAB A has a higher such ratio than 91.48% of stocks in our set.
- GMAB's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 9.59% of US stocks.
- If you're looking for stocks that are quantitatively similar to GENMAB A, a group of peers worth examining would be NVEC, GNFT, EXEL, IKT, and VCNX.
- Visit GMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.genmab.com.
GMAB Stock Price Chart Interactive Chart >
GMAB Price/Volume Stats
| Current price | $37.76 | 52-week high | $47.50 |
| Prev. close | $37.56 | 52-week low | $26.19 |
| Day low | $37.58 | Volume | 337,100 |
| Day high | $37.89 | Avg. volume | 529,711 |
| 50-day MA | $37.75 | Dividend yield | N/A |
| 200-day MA | $37.81 | Market Cap | 24.91B |
Genmab A/S ADR (GMAB) Company Bio
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US. (Source:Wikipedia)
Latest GMAB News From Around the Web
Below are the latest news stories about GENMAB A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsCompany Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The vesting of the restricted stock units granted to Jan G. J. van de Winkel and Anthony Pagano will be subject to forward looking performance criteria a |
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in GenmabCompany Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 90,054 restricted stock units to members of management and employees of the Company and the Company’s subsidiaries and 16,276 warrants to the employees of the Compa |
Passing of Genmab A/S’ Annual General MeetingCompany Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2023, the Annual Report for 2022 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2022 Compensation Report was approvedSix members of the Board of Directors were re-electedPricewaterhouseCoopers was re-elected as auditor of the CompanyThe proposals from the Board of Directors on the Board of Directors' remuneration for 2023, the propos |
Genmab Announces Appointment of Martine van Vugt to Chief Strategy OfficerMedia ReleaseCOPENHAGEN, Denmark; March 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that Martine van Vugt has been appointed to Chief Strategy Officer and promoted to Executive Vice President effective March 29, 2023. Martine will oversee Corporate Strategy, Corporate Development, Business Development and Licensing and Alliance Management. Martine joined Genmab in 2001 and most recently served as Genmab’s Senior Vice President, Corporate Strategy & Planning. She will continue her role as |
15 Most Profitable Growth Stocks NowIn this article, we will discuss the 15 Most Profitable Growth Stocks Now. You can skip our industry overview and go directly to the 5 Most Profitable Growth Stocks Now. Growth stocks refer to listed companies that are growing their profits, revenue, or cash flow at a rate that exceeds their competitors and beats the overall […] |
GMAB Price Returns
| 1-mo | 3.78% |
| 3-mo | -10.90% |
| 6-mo | 11.72% |
| 1-year | 3.06% |
| 3-year | 88.33% |
| 5-year | 76.56% |
| YTD | -10.90% |
| 2022 | 7.13% |
| 2021 | -2.71% |
| 2020 | 82.09% |
| 2019 | 35.54% |
| 2018 | -0.61% |
Loading social stream, please wait...